Drägerwerk AG & Co. KGaA — Cyborg Score 7/10

Strategic Profile

The medical division, which contributes the majority of revenue, operates five business units: Therapy, Hospital Consumables & Accessories, Workplace Infrastructure, Monitoring, and Data Business. With over 16,000 employees across 190 countries and production facilities on multiple continents, the company maintains strong global reach with approximately 80% of revenue generated outside Germany.

Cyborg Score Rationale

Drägerwerk demonstrated strong demand and robust earnings performance in the first nine months of 2025. The company reported highest demand in five years with a surge in order intake in H1 2025. Recent financial growth and expanding order book position the company well despite flat revenue at €3.37B.

Top Insights

• Strong performance in first nine months of 2025 with remarkable growth and robust earnings
• Highest demand in five years marked by surge in order intake in H1 2025
• 2024 earnings increased 12.65% year-over-year despite flat revenue
• Family-owned business founded in 1889, now in fifth generation as publicly listed global conglomerate

Named Competitors

• Patient Monitoring and Ventilation Systems — Medical device and healthcare solutions provider
• Respiratory Protection and Gas Detection — Personal protective equipment and safety solutions
• Patient Monitoring Systems — Medical equipment manufacturer

Recent Developments

• (October 2025) Strong Q3 2025 performance with significant boosts in sales and profitability across divisions
• (April 2025) Q1 2025 results showed strong order intake of EUR 861 million with promising growth outlook
• (March 2025) Increased net profit in fiscal 2024 and raised dividend

Open the full interactive Drägerwerk AG & Co. KGaA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.